EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome‐lysosome Fusion in NSCLC

Weina Guo, Haifeng Zhou, Jingbo Wang, Junjie Lu, Yalan Dong, Zhenyu Kang, Xiaoyuan Qiu, Xiaohu Ouyang, Qianyun Chen, Junyi Li, Xiang Cheng, Keye Du und 16 weitere

Advanced Science · 2024-08 · 11 (31)

DOI: 10.1002/advs.202308307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.06.2024. Verfasst von Weina Guo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technol…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Autophagosomes, Lung Neoplasms, Lysosomes. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Provincial Natural Science Foundation of Traditional Chinese Medicine, The Foundation of Hubei Key Laboratory of Biological Targeted Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aloperine (ALO), a quinolizidine‐type alkaloid isolated from a natural Chinese herb, has shown promising antitumor effects. Nevertheless, its common mechanism of action and specific target remain elusive. Here, it is demonstrated that ALO inhibits the proliferation and migration of non‐small cell lung cancer cell lines in vitro and the tumor development in several mouse tumor models in vivo. Mechanistically, ALO inhibits the fusion of autophagosomes with lysosomes and the autophagic flux, leading to the accumulation of sequestosome‐1 (SQSTM1) and production of reactive oxygen species (ROS), thereby inducing tumor cell apoptosis and preventing tumor growth. Knockdown of SQSTM1 in cells inhibits ROS production and reverses ALO‐induced cell apoptosis. Furthermore, VPS4A is identified as a direct target of ALO, and the amino acids F153 and D263 of VPS4A are confirmed as the binding sites for ALO. Knockout of VPS4A in H1299 cells demonstrates a similar biological effect as ALO treatment. Additionally, ALO enhances the efficacy of the anti‐PD‐L1/TGF‐β bispecific antibody in inhibiting LLC‐derived subcutaneous tumor models. Thus, ALO is first identified as a novel late‐stage autophagy inhibitor that triggers tumor cell death by targeting VPS4A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAutophagosomesLung NeoplasmsLysosomesQuinolizidinesAnimalsMiceHumansCell Line, TumorDisease Models, AnimalVesicular Transport ProteinsDisease ProgressionCell ProliferationAutophagyApoptosis

Stichwörter der Autor:innen

VPS4Aapoptosisautophagy inhibitionnon‐small cell lung cancersequestosome‐1

Substanzen

QuinolizidinesaloperineVesicular Transport Proteins

Autor:innen und Institutionen

  • Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
  • Department of Laboratory Medicine, Wuhan Children's Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
  • Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, 441000, China.
  • Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Department of Neurosurgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
  • Department of Gastroenterology, Zhongda Hospital, Southeast University, Nanjing, 210000, China.

ORCID-Profile: Desheng Hu

Förderung

  • National Natural Science Foundation of China
  • Hubei Provincial Natural Science Foundation of Traditional Chinese Medicine
  • The Foundation of Hubei Key Laboratory of Biological Targeted Therapy

Zitieren

APA

Guo, W., Zhou, H., Wang, J., Lu, J., Dong, Y., Kang, Z., Qiu, X., Ouyang, X., Chen, Q., Li, J., Cheng, X., Du, K., Li, M., Lin, Z., Jin, M., Zhang, L., Sarapultsev, A., Shi, K., Li, F., …, & Hu, D. (2024). Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome‐lysosome Fusion in NSCLC. Advanced Science, 11(31). https://doi.org/10.1002/advs.202308307

Vancouver

Guo W, Zhou H, Wang J, Lu J, Dong Y, Kang Z, et al. Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome‐lysosome Fusion in NSCLC. Advanced Science. 2024;11(31). doi:10.1002/advs.202308307

BibTeX
@article{Guo2024,
  author = {Guo, Weina and Zhou, Haifeng and Wang, Jingbo and Lu, Junjie and Dong, Yalan and Kang, Zhenyu and Qiu, Xiaoyuan and Ouyang, Xiaohu and Chen, Qianyun and Li, Junyi and Cheng, Xiang and Du, Keye and Li, Mingyue and Lin, Zhihao and Jin, Min and Zhang, Lei and Sarapultsev, Alexey and Shi, Kuangyu and Li, Fangfei and Zhang, Ge and Wu, Kongming and Rong, Yueguang and Heissmeyer, Vigo and Liu, Yue and Li, Yunlun and Huang, Kun and Luo, Shanshan and Hu, Desheng},
  title = {Aloperine Suppresses Cancer Progression by Interacting with VPS4A to Inhibit Autophagosome‐lysosome Fusion in NSCLC},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {31},
  doi = {10.1002/advs.202308307}
}
Kostenlos starten →